College of Medicine, Seoul National University, Seoul, Korea.
Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Korea.
J Korean Med Sci. 2020 Jul 20;35(28):e222. doi: 10.3346/jkms.2020.35.e222.
Uric acid (UA) has been suggested as a possible biomarker of bipolar disorder (BD) in recent studies. We aimed to provide a clearer comparison of UA levels between BD and major depressive disorder (MDD).
We retrospectively reviewed the medical chart records of psychiatric inpatients aged 19-60 years, whose main discharge diagnoses were either MDD or BD, with an admission between January 1, 2015 and December 31, 2018 at Seoul National University Hospital. Data such as sex, age, body mass index (BMI), medication usage, and serum UA levels were extracted. Patients with medical conditions or on medications that could influence UA levels were excluded. Age, sex, BMI, and psychiatric drug usage were considered in the comparison of serum UA between MDD and BD patients.
Our sample consisted of 142 MDD patients and 234 BD patients. The BD patients had significantly higher serum UA levels compared to the MDD patients, without accounting for other confounding variables (5.75 ± 1.56 mg/dL vs. 5.29 ± 1.59 mg/dL, = 0.006). -test comparisons between psychiatric medication users and non-users revealed that mood stabilizers and antipsychotics may be relevant confounding factors in our sample analysis. The likelihood of BD diagnosis was significantly correlated with higher UA levels (odds ratio, 1.410; 95% confidence interval, 1.150-1.728; = 0.001) when accounting for sex, age, and BMI in the logistic regression analysis. Also, accounting for mood stabilizers or antipsychotics, the likelihood of BD diagnosis was still significantly correlated with higher UA levels.
Our study confirms that BD patients are significantly more likely to show higher serum UA levels than MDD patients. The high UA levels in BD point to purinergic dysfunction as an underlying mechanism that distinguishes BD from MDD. Further research is recommended to determine whether UA is a trait or a state marker and whether UA correlates with the symptoms and severity of BD.
尿酸(UA)在最近的研究中被认为是双相障碍(BD)的一个可能的生物标志物。我们旨在更清楚地比较 BD 和重度抑郁症(MDD)之间的 UA 水平。
我们回顾性地审查了 2015 年 1 月 1 日至 2018 年 12 月 31 日期间在首尔国立大学医院住院的 19-60 岁精神科住院患者的病历记录,其主要出院诊断为 MDD 或 BD。提取了性别、年龄、体重指数(BMI)、用药情况和血清 UA 水平等数据。排除有影响 UA 水平的医疗条件或用药的患者。在比较 MDD 和 BD 患者的血清 UA 时,考虑了年龄、性别、BMI 和精神科药物使用情况。
我们的样本包括 142 名 MDD 患者和 234 名 BD 患者。BD 患者的血清 UA 水平明显高于 MDD 患者,而未考虑其他混杂变量(5.75±1.56mg/dL 比 5.29±1.59mg/dL, = 0.006)。精神病药物使用者和非使用者之间的 t 检验比较表明,心境稳定剂和抗精神病药物可能是我们样本分析中的相关混杂因素。在逻辑回归分析中,考虑到性别、年龄和 BMI,BD 诊断的可能性与较高的 UA 水平显著相关(优势比,1.410;95%置信区间,1.150-1.728; = 0.001)。此外,即使考虑到心境稳定剂或抗精神病药物,BD 诊断的可能性仍与较高的 UA 水平显著相关。
我们的研究证实,BD 患者的血清 UA 水平明显高于 MDD 患者。BD 患者的高 UA 水平表明嘌呤能功能障碍是区分 BD 和 MDD 的潜在机制。建议进一步研究以确定 UA 是特质还是状态标志物,以及 UA 是否与 BD 的症状和严重程度相关。